Newsroom der German Breast Group
In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group.
04.01.2021 AGO-Mamma State of the Art Meeting
Save the date: Virtuelles State of the Art Meeting am 27. Februar.
11.12.2020 November 2020: Effect of neoadjuvant chemotherapy on immune system in patients with TNBC
A translational research project evaluating effect of chemotherapy on different immune subsets in TNBC patients from GeparNuevo trial was published in Journal for ImmunoTherapy of Cancer
09.12.2020 GBG Research at SABCS Virtual Meeting 2020
Data on GBG study PenelopeB and several collaborative projects will be presented at the SABCS Virtual Meeting 2020.
13.11.2020 October 2020: Results from GeparOLA study
We are delighted to inform you that results from GeparOLA trial have been published in Annals of Oncology.
07.11.2020 GeparDouze-1000ste Patient randomisiert!
NSABP und GBG freuen sich bekannt zu geben, dass der 1000. Patient für die GeparDouze-Studie randomisiert wurde.
23.10.2020 September 2020: Clinical Outcome of Breast Cancer Patients with asymptomatic brain metastases.
Analysis of breast cancer patients with asymptomatic brain metastases from BMBC registry has been published in Cancers (Basel).
23.10.2020 August 2020: MGMT promoter methylation in TNBC
A translational research project evaluating the MGMT promoter methylation status in TNBC from GeparSixto has been published in PLoSOne
09.10.2020 ICH BIN DABEI! Brustkrebs verstehen.
Kampagne „ICH BIN DABEI! Brustkrebs verstehen – wir unterstützen die Veranstaltung!
09.10.2020 PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint
PENELOPE-B trial did not meet the primary endpoint of improved invasive disease-free survival in women with hormone receptor-positive, human epidermal growth factor-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy. No unexpected safety signals were observed.
14.09.2020 GBG Research at ESMO Virtual Meeting 2020
Data of several GBG studies was presented at the upcoming ESMO Virtual Meeting 2020, which took place from 19 to 21 September 2020.
22.07.2020 Gleiche Heilungschancen, mehr Lebensqualität?
Große internationale Multicenter-Studie (TAXIS) vergleicht zwei chirurgische Therapiekonzepte bei Brustkrebs mit Lymphknotenbefall / Prof. Dr. Jörg Heil
14.07.2020 July 2020: Tumor mutational burden and immune gene expression in GeparNuevo trial
A research project investigating tumor mutational burden and immune gene expression profile for response to neoadjuvant treatment in early TNBC has been published in Annals of Oncology
16.06.2020 June 2020: Central review of INSEMA radiotherapy planning
We are delighted to inform you that results from a quality assurance process integrated into the INSEMA trial have been published in International Journal of Radiation Oncology, Biology, Physics.
30.05.2020 Update on PALLAS, an International Academic Breast Cancer Study Evaluating Adjuvant Palbociclib
Second Interim Analysis of Adjuvant Study for HR+, HER2- Early Breast Cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence
27.05.2020 GBG Research presented at ASCO 2020
Data on several research projects from GBG and collaborative groups will be presented at the upcoming ASCO Virtual Meeting 2020, which will take place from 29 to 31 May 2020.
18.05.2020 GBG Research at ESMO Breast Cancer Virtual Meeting 2020
Data of several GBG research projects will be presented at the upcoming ESMO Breast Cancer Virtual Meeting 2020, which will take place from 23 to 24 May 2020.
18.05.2020 Locoregional recurrence risk after neoadjuvant chemotherapy
A pooled analysis of nine prospective neoadjuvant breast cancer trials that aimed to identify independent predictors of Locoregional recurrence risk after neoadjuvant chemotherapy has been published in European Journal of Cancer.
06.05.2020 ESMO BREAST CANCER Virtual Meeting
ESMO BREAST CANCER Virtual Meeting 2020 23-24. May 2020
30.04.2020 A small hypoxia signature predicts response to neoadjuvant bevacizumab treatment
A translational research project aiming to identify predictive markers for response to bevacizumab treatment in HER2-negative breast cancer from GeparQuinto study has been published in Clinical Cancer Research.
